- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01211665
Corticosteroids for Immune Reconstitution Inflammatory Syndrome (IRIS) (IRIS)
August 26, 2014 updated by: Biogen
High-Dose Corticosteroids for Immune Reconstitution Inflammatory Syndrome in Patients Who Develop Progressive Multifocal Leukoencephalopathy on Natalizumab
The objectives of this study are to explore the effects of administering high-dose corticosteroids to participants who developed progressive multifocal leukoencephalopathy (PML) while on natalizumab as measured by time-course change in functional status based on Karnofsky Performance Status Index through 6 months following the completion of plasma exchange (PLEX; or equivalent), survival at 6 months following the completion of PLEX (or equivalent), and incidence and severity of adverse events (AEs) and serious adverse events (SAEs); to characterize the evolution of immune reconstitution inflammatory syndrome (IRIS) as measured by time course changes in Global Clinical Impression of Improvement (GCI-I), Symbol Digit Modalities Test (SDMT), brain magnetic resonance imaging (MRI), magnetoencephalography (MEG), chemokines, cytokines, C-reactive protein (CRP), John Cunningham virus (JCV) load and cell count in cerebrospinal fluid (CSF); and to characterize the time course elimination of serum natalizumab concentrations in the study population following the last PLEX (or equivalent) procedure.
Study Overview
Status
Terminated
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
3
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Bochum, Germany
- Research Site
-
Wurzburg, Germany
- Research Site
-
-
-
-
Nebraska
-
Hastings, Nebraska, United States
- Research Site
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Key Inclusion Criteria:
- Must have been receiving natalizumab for multiple sclerosis (MS) prior to the diagnosis or suspicion of Progressive multifocal leukoencephalopathy (PML).
- Subject must be willing to undergo or have completed plasma exchange (PLEX) prior to initiating study treatment.
Key Exclusion Criteria:
- History of severe allergic or anaphylactic reactions or known hypersensitivity to any drug including hypersensitivity to corticosteroids.
NOTE: Other protocol defined inclusion/exclusion criteria may apply.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NON_RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Pulsed IVMP
Intravenous methylprednisolone (IVMP) 1 g/day administered the first 3 days of each weekly cycle, and repeated for 3 additional cycles (totaling 4 cycles).
If necessary, 2 additional weekly cycles of 1 g IVMP daily for 3 days can be administered at the discretion of the investigator.
|
In intravenous form (for a daily dose of 1 g/day on treatment days).
Other Names:
|
EXPERIMENTAL: IVMP with oral prednisolone taper
Intravenous methylprednisolone (IVMP) 1g/day for 6 days followed by an oral taper of prednisolone over 2 months (suggested dosages starting at 80 mg and tapering to 5 mg).
If necessary, additional cycles of 1 g IVMP daily for 3 to 5 days can be administered at any time.
|
In intravenous form (for a daily dose of 1 g/day on treatment days).
Other Names:
Oral prednisolone used as a taper, with suggested dosages starting at 80 mg and tapering to 5 mg.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Time Course Change in Functional Status Based on Karnofsky Performance Status Index Through 6 Months Following Completion of Plasma Exchange (PLEX)
Time Frame: Baseline up to 6 months
|
The Karnofsky Performance Status Index (KPSI) is an assessment tool intended to assist clinicians and caretakers in gauging a patient's functional status and ability to carry out activities of daily living.
A KPSI of 100=normal, no complaints, no evidence of disease; 90=able to carry on normal activity, minor signs or symptoms of disease; 80=normal activity with effort, some signs or symptoms of disease; 70=cares for self, unable to carry on normal activity or do active work; 60=requires occasional assistance but is able to care for most personal needs; 50=requires considerable assistance and frequent medical care; 40=disabled, requires special care and assistance; 30=severely disabled, hospitalization is indicated, although death is not imminent; 20=very sick, hospitalization is necessary, active support treatment is necessary; 10=moribund, fatal processes progressing rapidly; 0=dead.
|
Baseline up to 6 months
|
Number of Participants Who Survived at 6 Months Following Completion of Plasma Exchange (PLEX)
Time Frame: 6 months
|
Following the completion of rapid removal of natalizumab using PLEX or equivalent.
|
6 months
|
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
Time Frame: from the first dose of study treatment through the end of the treatment period (6 months) + a 4-week post-treatment period
|
AE=any untoward medical occurrence in a participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment.
SAE=any untoward medical occurrence that at any dose: results in death; in the view of the Investigator, places the participant at immediate risk of death (a life-threatening event); however, this does not include an event that, had it occurred in a more severe form, might have caused death; requires hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; or results in a congenital anomaly/birth defect.
An SAE may also be any other medically important event that, in the opinion of the Investigator, may jeopardize the participant or may require intervention to prevent one of the other outcomes listed in the definition above.
|
from the first dose of study treatment through the end of the treatment period (6 months) + a 4-week post-treatment period
|
Severity of AEs and SAEs
Time Frame: from the first dose of study treatment through the end of the treatment period (6 months) + a 4-week post-treatment period
|
AEs and SAEs were categorized as mild, moderate or severe according to the following criteria: Mild=barely noticeable to participant or does not make participant uncomfortable; does not influence performance or functioning; prescription drug not ordinarily needed for relief of symptom(s) but may be given because of personality of participant.
Moderate=of a sufficient severity to make participant uncomfortable; performance of daily activity is influenced; participant is able to continue in study; treatment for symptom(s) may be needed.
Severe=symptoms cause severe discomfort; symptoms cause incapacity or significant impact on participant's daily life; severity may cause cessation of treatment with study treatment; treatment for symptom(s) may be given and/or participant hospitalized.
Please see Outcome Measure 3 for AE and SAE definitions.
|
from the first dose of study treatment through the end of the treatment period (6 months) + a 4-week post-treatment period
|
Time Course Change in the Global Clinical Impression of Improvement (GCI-I) Scale
Time Frame: Screening to 6 months following completion of PLEX (participants began treatment with intravenous methylprednisolone (IVMP) within 2 weeks after PLEX [or equivalent]).
|
The GCI-I scale is a 7-point scale that assesses how much the participant's illness has improved or worsened relative to a baseline state at the beginning of the intervention, and rates it as: 1=very much improved; 2=much improved; 3=minimally improved; 4=no change; 5=minimally worse; 6=much worse; 7=very much worse.
|
Screening to 6 months following completion of PLEX (participants began treatment with intravenous methylprednisolone (IVMP) within 2 weeks after PLEX [or equivalent]).
|
Time Course Change in Cerebral Dysfunction Using the Symbol Digit Modalities Test (SDMT)
Time Frame: Screening to 6 months following completion of PLEX (participants began treatment with IVMP within 2 weeks after PLEX [or equivalent]).
|
The SDMT measures the time to pair abstract symbols with specific numbers.
The test requires elements of attention, visuoperceptual processing, working memory, and psychomotor speed.
The score is the number of correctly coded items from 0-110 in 90 seconds.
The total score provides a measure of the speed and accuracy of symbol-digit substitution.
|
Screening to 6 months following completion of PLEX (participants began treatment with IVMP within 2 weeks after PLEX [or equivalent]).
|
Time Course Changes in Brain Magnetic Resonance Imaging (MRI)
Time Frame: Screening to 6 months following completion of PLEX (participants began treatment with IVMP within 2 weeks after PLEX [or equivalent]).
|
The brain MRI data collected included: progressive multifocal leukoencephalopathy (PML) lesion localization, T2 hyperintense lesion volume, and signs of cerebral edema.
|
Screening to 6 months following completion of PLEX (participants began treatment with IVMP within 2 weeks after PLEX [or equivalent]).
|
Time Course Change in Magnetoencephalography (MEG) Results
Time Frame: Screening to 6 months following completion of PLEX (participants began treatment with IVMP within 2 weeks after PLEX [or equivalent]).
|
MEG was used to map brain activity.
|
Screening to 6 months following completion of PLEX (participants began treatment with IVMP within 2 weeks after PLEX [or equivalent]).
|
Time Course Change in Clinical Laboratory Values
Time Frame: Screening to 6 months following completion of PLEX (participants began treatment with IVMP within 2 weeks after PLEX [or equivalent]).
|
Clinical laboratory values included chemokines, cytokines, C-reactive protein (CRP), John Cunningham (JC) virus load, and cell count in cerebrospinal fluid.
|
Screening to 6 months following completion of PLEX (participants began treatment with IVMP within 2 weeks after PLEX [or equivalent]).
|
Time Course Elimination of Serum Natalizumab Concentration Following Plasma Exchange (PLEX) or Equivalent
Time Frame: Baseline up to 6 months
|
Baseline up to 6 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
September 1, 2010
Primary Completion (ACTUAL)
February 1, 2012
Study Completion (ACTUAL)
February 1, 2012
Study Registration Dates
First Submitted
July 29, 2010
First Submitted That Met QC Criteria
September 28, 2010
First Posted (ESTIMATE)
September 29, 2010
Study Record Updates
Last Update Posted (ESTIMATE)
September 5, 2014
Last Update Submitted That Met QC Criteria
August 26, 2014
Last Verified
August 1, 2014
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Virus Diseases
- Infections
- Immune System Diseases
- Demyelinating Diseases
- Disease
- Encephalitis, Viral
- Central Nervous System Viral Diseases
- Central Nervous System Infections
- Infectious Encephalitis
- DNA Virus Infections
- Slow Virus Diseases
- Encephalitis
- Polyomavirus Infections
- Syndrome
- Leukoencephalopathy, Progressive Multifocal
- Leukoencephalopathies
- Immune Reconstitution Inflammatory Syndrome
- Physiological Effects of Drugs
- Autonomic Agents
- Peripheral Nervous System Agents
- Anti-Inflammatory Agents
- Antineoplastic Agents
- Antiemetics
- Gastrointestinal Agents
- Glucocorticoids
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Antineoplastic Agents, Hormonal
- Neuroprotective Agents
- Protective Agents
- Prednisolone
- Methylprednisolone Acetate
- Methylprednisolone
- Methylprednisolone Hemisuccinate
- Prednisolone acetate
- Prednisolone hemisuccinate
- Prednisolone phosphate
Other Study ID Numbers
- 101JC404
- 2010-020369-26 (EUDRACT_NUMBER)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Leukoencephalopathy, Progressive Multifocal
-
Fondation Ophtalmologique Adolphe de RothschildCompletedAIDS | Progressive Multifocal Leucoencephalopathy (PML)
-
BiogenTerminatedProgressive Multifocal LeukoencephalopathyUnited States, Germany
-
Cellevolve Bio IncNot yet recruitingProgressive Multifocal Leukoencephalopathy
-
First Affiliated Hospital of Zhejiang UniversityUnknownProgressive Multifocal Leukoencephalopathy | AIDSChina
-
National Institute of Neurological Disorders and...CompletedProgressive Multifocal LeukoencephalopathyUnited States
-
University Hospital, ToulouseRecruitingProgressive Multifocal LeukoencephalopathyFrance
-
Fondation Ophtalmologique Adolphe de RothschildCompletedProgressive Multifocal Leukoencephalopathy
-
BiogenElan PharmaceuticalsTerminatedProgressive Multifocal LeukoencephalopathyUnited States, Brazil, Italy, Spain, Germany
-
BiogenCompletedProgressive Multifocal LeukoencephalopathyUnited States
-
National Institute of Allergy and Infectious Diseases...Bristol-Myers Squibb; UpjohnCompletedHIV Infections | Leukoencephalopathy, Progressive MultifocalUnited States
Clinical Trials on Methylprednisolone
-
Rennes University HospitalUnknownMultiple Sclerosis, Relapsing-RemittingFrance
-
Chang Gung Memorial HospitalRecruitingMucocutaneous Lymph Node SyndromeTaiwan
-
Fred LublinPfizer; National Multiple Sclerosis SocietyTerminatedMultiple SclerosisUnited States
-
Assistance Publique - Hôpitaux de ParisCompleted
-
Universidad Nacional Autonoma de MexicoInstituto Nacional de Neurología y NeurocirugíaEnrolling by invitationMethylprednisolone | Intranasal Administration | Patients With an Active Multiple Sclerosis RelapseMexico
-
LEO PharmaBayerCompleted
-
Assiut UniversityCompleted
-
University of Colorado, DenverUniversity of Pennsylvania; MallinckrodtTerminatedMultiple SclerosisUnited States
-
Fundação de Medicina Tropical Dr. Heitor Vieira...CompletedSARS-CoV Infection | Severe Acute Respiratory Syndrome (SARS) PneumoniaBrazil
-
Peking University People's HospitalBeijing HospitalUnknownImmune Thrombocytopenia